Pharmacogenomics: From Basic Research to Clinical Implementation

Affiliations

Editorial

Laura B Scheinfeldt. J Pers Med. 2021.

. 2021 Aug 17;11(8):800.

doi: 10.3390/jpm11080800.

Abstract

The established contribution of genetic variation to drug response has the potential to improve drug efficacy and reduce drug toxicity [...].

The author declares no conflict of interest.

1. Scheinfeldt L.B., Brangan A., Kusic D.M., Kumar S., Gharani N. Common Treatment, Common Variant: Evolutionary Prediction of Functional Pharmacogenomic Variants. J. Pers. Med. 2021;11:131. doi: 10.3390/jpm11020131. - DOI - PMC - PubMed
1. Han N., Oh J.M., Kim I.W. Combination of Genome-Wide Polymorphisms and Copy Number Variations of Pharmacogenes in Koreans. J. Pers. Med. 2021;11:33. doi: 10.3390/jpm11010033. - DOI - PMC - PubMed
1. Lee F.Y., Islahudin F., Ali Nasiruddin A.Y., Abdul Gafor A.H., Wong H.S., Bavanandan S., Mohd Saffian S., Md Redzuan A., Mohd Tahir N.A., Makmor-Bakry M. Effects of CYP3A5 Polymorphism on Rapid Progression of Chronic Kidney Disease: A Prospective, Multicentre Study. J. Pers. Med. 2021;11:252. doi: 10.3390/jpm11040252. - DOI - PMC - PubMed
1. Kim J.A., Ceccarelli R., Lu C.Y. Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020) J. Pers. Med. 2021;11:179. doi: 10.3390/jpm11030179. - DOI - PMC - PubMed
1. Silva P., Jacobs D., Kriak J., Abu-Baker A., Udeani G., Neal G., Ramos K. Implementation of Pharmacogenomics and Artificial Intelligence Tools for Chronic Disease Management in Primary Care Setting. J. Pers. Med. 2021;11:443. doi: 10.3390/jpm11060443. - DOI - PMC - PubMed